Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;59(1):17-22.
doi: 10.1038/s41409-023-02107-z. Epub 2023 Sep 25.

Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment

Affiliations

Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment

Giuseppe Milone et al. Bone Marrow Transplant. 2024 Jan.

Abstract

We conducted a prospective study aimed at investigating the prognostic value of the dynamic of a-GVHD progression from cutaneous to visceral involvement. In 108 consecutive patients who underwent allogeneic HSCT, we classified a-GVHD according to a "GHVD skin dynamic": 18/82 patients started Corticosteroid (CS) within 48 h (Group 1); 13/82 started CS within days 3-7 (Group 2); Group 3A (n 31) was defined when Skin GVHD Overall Grade 1, left untreated for 1 week, showed an increase in involved body surface area <5 %; Group 3B (n 20), was defined when Skin GVHD Overall Grade 1, left untreated at 1 week, had an increase in involved body surface area >5%. These four groups had distinctive 2-y OS. Patients could be then grouped into "poor risk" (Group 1 and Group 3B) and "good risk" (Group 2 and Group 3A). "Poor risk" had inferior OS in univariate and multivariate analysis, (HR 2.222; 95% CL: 1.017-4.855; p 0.04). Among the patients with skin-only Grade 1 GVHD, subgroup 3A had an OS of 75.1% versus 39.8% found in subgroup 3B (p = 0.03). The dynamic of skin GVHD may be used to classify a-GVHD and guide treatment in Overall Grade 1 skin-only GVHD.

PubMed Disclaimer

Similar articles

References

    1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell trans-plantation. N Engl J Med. 2010;363:2091–101. - DOI - PubMed - PMC
    1. Dalle JH, Giralt SA. Hepatic Veno-Occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl. 2016;22:400–9. https://doi.org/10.1016/j.bbmt.2015.09.024 . - DOI
    1. Patel SS, Ahn KW, Khanal M, Bupp C, Allbee-Johnson M, Majhail NS, et al. Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation. Transplant Cell Ther. 2022;28:310–20. https://doi.org/10.1016/j.jtct.2022.03.015 . - DOI - PubMed - PMC
    1. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304. https://doi.org/10.1097/00007890-197410000-00001 . - DOI - PubMed
    1. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 consensus conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8. - PubMed

MeSH terms

Substances

LinkOut - more resources